Detalles de la búsqueda
1.
Lecanemab in Early Alzheimer's Disease.
N Engl J Med
; 388(1): 9-21, 2023 01 05.
Artículo
Inglés
| MEDLINE | ID: mdl-36449413
2.
Change in Cerebrospinal Fluid Tau Microtubule Binding Region Detects Symptom Onset, Cognitive Decline, Tangles, and Atrophy in Dominantly Inherited Alzheimer's Disease.
Ann Neurol
; 93(6): 1158-1172, 2023 06.
Artículo
Inglés
| MEDLINE | ID: mdl-36843330
3.
Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users.
J Clin Psychopharmacol
; 42(4): 374-382, 2022.
Artículo
Inglés
| MEDLINE | ID: mdl-35748777
4.
Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users.
J Clin Psychopharmacol
; 42(4): 365-373, 2022.
Artículo
Inglés
| MEDLINE | ID: mdl-35749758
5.
E2027 Cardiac Safety Evaluation With Concentration-Response Modeling of ECG Data to Inform Dose Selection in Studies in Patients With Dementia With Lewy Bodies.
Alzheimer Dis Assoc Disord
; 36(3): 208-214, 2022.
Artículo
Inglés
| MEDLINE | ID: mdl-35622456
6.
Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial.
Alzheimer Dis Assoc Disord
; 36(3): 200-207, 2022.
Artículo
Inglés
| MEDLINE | ID: mdl-35700341
7.
Use of extended-release and immediate-release anti-seizure medications with a long half-life to improve adherence in epilepsy: A guide for clinicians.
Epilepsy Behav
; 120: 107993, 2021 07.
Artículo
Inglés
| MEDLINE | ID: mdl-33971390
8.
Bioequivalence of perampanel fine granules and tablets in healthy Japanese subjects.
Int J Clin Pharmacol Ther
; 58(12): 757-764, 2020 Dec.
Artículo
Inglés
| MEDLINE | ID: mdl-32870153
9.
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
Br J Cancer
; 120(6): 579-586, 2019 03.
Artículo
Inglés
| MEDLINE | ID: mdl-30783204
10.
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
Br J Cancer
; 120(4): 379-386, 2019 02.
Artículo
Inglés
| MEDLINE | ID: mdl-30679780
11.
Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study.
Br J Cancer
; 118(12): 1580-1585, 2018 06.
Artículo
Inglés
| MEDLINE | ID: mdl-29867224
12.
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Pediatr Blood Cancer
; 65(8): e27066, 2018 08.
Artículo
Inglés
| MEDLINE | ID: mdl-29719113
13.
A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.
Invest New Drugs
; 31(4): 900-9, 2013 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-23143778
14.
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
Br J Clin Pharmacol
; 75(2): 507-15, 2013 Feb.
Artículo
Inglés
| MEDLINE | ID: mdl-22803519
15.
Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia.
J Clin Pharmacol
; 63(4): 498-511, 2023 04.
Artículo
Inglés
| MEDLINE | ID: mdl-36524428
16.
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.
Alzheimers Dement (N Y)
; 9(1): e12377, 2023.
Artículo
Inglés
| MEDLINE | ID: mdl-36949897
17.
A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease.
CPT Pharmacometrics Syst Pharmacol
; 12(4): 444-461, 2023 04.
Artículo
Inglés
| MEDLINE | ID: mdl-36632701
18.
Mass balance study of [¹4C]eribulin in patients with advanced solid tumors.
Drug Metab Dispos
; 40(2): 313-21, 2012 Feb.
Artículo
Inglés
| MEDLINE | ID: mdl-22041109
19.
Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.
Eur J Clin Pharmacol
; 68(3): 249-58, 2012 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-21935705
20.
No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.
Eur J Clin Pharmacol
; 68(3): 291-300, 2012 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-21969227